Developing World Bioethics 15 (2):85-97 (2015)
AbstractThe principle of providing post-trial access for research participants to successful products of that research is widely accepted and has been enshrined in various declarations and guidelines. While recent ethical guidelines recognise that the responsibility to provide post-trial access extends to sponsors, regulators and government bodies as well as to researchers, it is the researchers who have the direct duty of care to participants. Researchers may thus need to act as advocates for trial participants, especially where government bodies, sponsors, and regulatory bodies have complex interests vested in decisions about whether or not new interventions are made available, how, and to whom. This paper provides an empirical account of post-trial access in the context of HIV prevention research. It describes both access to the successful products of research and the provision antiretroviral drugs for trial participants who acquire HIV. First, we provide evidence that, in the current system, there is considerable variation in the duration and timeliness of access. We then argue that by analysing the difficulties faced by researchers to this point, and their efforts to meet this obligation, much can be learned about how to secure post-trial access in HIV biomedical preventions trials. While researchers alone have a limited obligation, their advocacy on behalf of trial participants may be necessary to call the other parties to account
Similar books and articles
Should Post-Trial Provision of Beneficial Experimental Interventions Be Mandatory in Developing Countries?Z. Zong - 2008 - Journal of Medical Ethics 34 (3):188-192.
Pharmaceutical Companies Vs. The State: Who Is Responsible for Post-Trial Provision of Drugs in Brazil?Daniel Wei L. Wang & Octavio Luiz Motta Ferraz - 2012 - Journal of Law, Medicine and Ethics 40 (2):188-196.
Ethical Considerations in Determining Standard of Prevention Packages for HIV Prevention Trials: Examining PrEP.Bridget Haire, Morenike Oluwatoyin Folayan, Catherine Hankins, Jeremy Sugarman, Sheena McCormack, Gita Ramjee & Mitchell Warren - 2013 - Developing World Bioethics 13 (2):87-94.
Access to Treatment in Hiv Prevention Trials: Perspectives From a South African Community.Nicola Barsdorf, Suzanne Maman, Nancy Kass & Catherine Slack - 2010 - Developing World Bioethics 10 (2):78-87.
Intertwining Biomedical Research and Public Health in HIV Microbicide Research.R. Macklin - 2010 - Public Health Ethics 3 (3):199-209.
Post-Trial Access to Study Medication: A Brazilian E-Survey with Major Stakeholders in Clinical Research.Sonia M. Dainesi & Moises Goldbaum - 2012 - Journal of Medical Ethics 38 (12):757-762.
Equitable Treatment for HIV/AIDS Clinical Trial Participants: A Focus Group Study of Patients, Clinician Researchers, and Administrators in Western Kenya.D. N. Shaffer - 2006 - Journal of Medical Ethics 32 (1):55-60.
Subjects' Views of Obligations to Ensure Post-Trial Access to Drugs, Care and Information: Qualitative Results From the Experiences of Participants in Clinical Trials (EPIC) Study.N. Sofaer, C. Thiessen, S. D. Goold, J. Ballou, K. A. Getz, G. Koski, R. A. Krueger & J. S. Weissman - 2009 - Journal of Medical Ethics 35 (3):183-188.
Reasons Why Post-Trial Access to Trial Drugs Should, or Need Not Be Ensured to Research Participants: A Systematic Review.N. Sofaer & D. Strech - 2011 - Public Health Ethics 4 (2):160-184.
Treatment Needs in Hiv Prevention Trials: Using Beneficence to Clarify Sponsor-Investigator Responsibilities.Melissa Stobie & Catherine Slack - 2010 - Developing World Bioethics 10 (3):150-157.
Ethical Tradeoffs in Trial Design: Case Study of an HPV Vaccine Trial in HIV‐Infected Adolescent Girls in Lower Income Settings.J. C. Lindsey, S. K. Shah, G. K. Siberry, P. Jean-Philippe & M. J. Levin - 2013 - Developing World Bioethics 13 (2):95-104.
Characterizing the Population in Clinical Trials: Barriers, Comparability, and Implications for Review.Charles Weijer - unknown
Added to PP
Historical graph of downloads
Citations of this work
Human Dignity as a Basis for Providing Post-Trial Access to Healthcare for Research Participants: A South African Perspective.Pamela Andanda & Jane Wathuta - 2018 - Medicine, Health Care and Philosophy 21 (1):139-155.
Implementing Post-Trial Access Plans for HIV Prevention Research.Amy Paul, Maria W. Merritt & Jeremy Sugarman - 2018 - Journal of Medical Ethics 44 (5):354-358.
Communities Need to Be Equal Partners in Determining Whether Research is Acceptable.Bridget G. Haire & John M. Kaldor - 2018 - Journal of Medical Ethics 44 (3):159-160.
“Reasonable Availability” Criterion Remains Salient.Bridget Gabrielle Haire - 2016 - American Journal of Bioethics 16 (6):19-21.
Undue Inducement, or Unfair Exclusion: Considering a Case Study of Pregnancy in an HIV Prevention Trial.Bridget G. Haire & Morenike Oluwatoyin Folayan - 2017 - Journal of Medical Ethics 43 (12):829-830.
References found in this work
Post‐Trial Access to Antiretrovirals: Who Owes What to Whom?Joseph Millum - 2011 - Bioethics 25 (3):145-154.
The Ambiguity and the Exigency: Clarifying 'Standard of Care' Arguments in International Research.Alex John London - 2000 - Journal of Medicine and Philosophy 25 (4):379 – 397.
Realizing Benefit Sharing – the Case of Post-Study Obligations.Doris Schroeder & Eugenijus Gefenas - 2012 - Bioethics 26 (6):305-314.
Realizing Benefit Sharing - the Case of Post-Study Obligations.Doris Schroeder & Eugenijus Gefenas - 2012 - Bioethics 26 (6):305-314.
Ethical Challenges in HIV Microbicide Research: What Protections Do Women Need?Ruth Macklin - 2011 - International Journal of Feminist Approaches to Bioethics 4 (2):124-143.